Hospital-Acquired Bacterial Pneumonia: Updated Strategies for Intravenous Antibiotic Coverage
Description
Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia remain major causes of morbidity and mortality in hospitalized patients, particularly in intensive care unit settings. The microbiological landscape is dominated by Gram-negative bacilli, including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii, as well as Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus. The growing prevalence of resistance mechanisms, including extended-spectrum beta-lactamases, carbapenem-resistant Enterobacterales, metallo-beta-lactamases, AmpC enzymes, efflux pumps, and porin loss, significantly complicates therapeutic decision-making and necessitates risk-adapted empirical strategies guided by local antibiograms. Pathophysiological mechanisms such as microaspiration, dysbiosis, biofilm formation on endotracheal tubes, impaired mucociliary clearance, and systemic inflammatory activation contribute to infection persistence and progression to severe complications, including sepsis. Risk factors for multidrug-resistant organisms include prolonged hospitalization, prior intravenous antibiotic exposure, septic shock, acute respiratory distress syndrome, renal replacement therapy, and immunosuppression. Early initiation of appropriate intravenous antibiotic therapy within the first 24 hours is essential to reduce mortality and improve outcomes. Empirical regimens should be tailored according to individual risk profiles, with broad-spectrum coverage reserved for high-risk patients and avoidance of unnecessary combination therapy. Updated regimens include antipseudomonal beta-lactams, carbapenems, new-generation beta-lactam/beta-lactamase inhibitor combinations, and agents such as cefiderocol for resistant pathogens. Rapid molecular diagnostics facilitate early de-escalation and optimization of treatment duration, while antimicrobial stewardship programs, preventive bundles, and infection control measures are critical to limiting resistance. Future strategies integrating novel antimicrobials, artificial intelligence, personalized dosing, and continuous surveillance are essential for sustained therapeutic effectiveness.